Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
This Special Issue on Cancer Metabolism contains a selection of articles that provide insights into a variety of ongoing questions in oncometabolism, to help drive the translation of these findings towards the clinic.
The expectation for survival in patients with advanced melanoma now exceeds 50% at 5 years in patients treated with first-line combination ipilimumab and nivolumab, despite this regimen being associated with substantial toxicity. We discuss the latest updates from the Checkmate-067 study, framing the role of this combination in practice today.
With an ever-growing body of oncology research, BJC Reviews seek to summarise and condense that information into thought-provoking commentaries. They cover a broad remit of oncology research, from the cellular and molecular events that underpin tumorigenesis and disease progression, to existing and emerging therapeutics and clinical cancer management. Our recent review articles are presented for you in this evolving Collection; we hope you enjoy reading them.